Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Anke Bergmann
Clinical and molecular characteristics of FLT3 -ITD microclones in elderly patients with acute myeloid leukemia receiving less-intensive therapy
To the Editor, Internal tandem duplications (ITD) of the FMS-like Tyrosinkinase 3 (FLT3) are detected in up to 30% of all newly diagnosed acute myeloid leukemia (AML) cases, with a decreasing prevalence in elderly patients [1]. FLT3-ITD positivity in AML patients predicts poor prognosis and shorter median overall survival (OS), corresponding to an intermediate genetic risk classification per the ELN 2024 less-intensive score [2].
Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia
To the Editor Despite targeted therapies including tyrosine kinase inhibitors (TKI) and immune effector cell-based approaches, BCR::ABL1+ acute lymphoblastic leukemia (ALL) remains a high-risk disease with allogeneic stem cell transplantation considered the best-established curative option. However, due to the age-dependency of BCR::ABL1+ ALL incidence and enhanced vulnerability of elderly patients, optimization of drug-based therapies remains an urgent clinical need [1, 2].
Priority European strategies for sustainable access to high-quality genetic counselling in cancer: A Delphi study - European Journal of Human Genetics
|
Abstract Europe’s Beating Cancer Plan is a substantial European Union (EU) investment into cancer prevention and treatment. Integration of genetic services towards personalised cancer prevention and care is a flagship of this plan. Genetic counselling is critical to this integration, facilitating informed patient decision making and improved clinical management.
By J. Matt McCrary, Els Van Valckenborgh, Denis Horgan Verified, Ralf Bargou, Regína Lohajová Behulová, Ivica Belina, Joan Brunet, Florin Burada, Adela Chirita-Emandi, Chrystelle Colas, Anastasia Constantinidou, Razvan-Ovidiu Curca, Viorica Cursaru, Miriam Dalmas, Zanda Daneberga, Evandro de Azambuja, Antoine de Pauw, Robin de Putter, Deirdre Donnelly, Hans Ehrencrona, Lenka Foretova, Fabrizia Galli, Maurizio Genuardi, Rachel Giles, Barbara Klink, Mateja Krajc, Joanna Kufel-Grabowska, Baiba Lace, Liis Leitsalu, Christophe Le Tourneau, Francesca Mari Verified, Francesca Marí Verified, Erika Matos, Luca Mazzarella, Tamara Hussong Milagre, Martin Mistrik, Barbara Moss, Amy Nolan Verified, Milena Paneque, Attila Patócs, Hélène A. Poirel, Manuel Jorge Rodrigues, Evelin Schröck, Gunda Schwaninger, Kostas Stamatopoulos, Krzysztof Szczałuba, Philippe Theis, Jacqueline Turner, Christopher Vella, Johannes Zschocke, Tim Ripperger, Anke Bergmann, Evgenia Aleksandrova, Andrada Ciuca, Turem Delikurt-Tuncalp, Claire Grima, Helena Kääriäinen, Marianne Lodahl, Rosie O’Shea, Rebecka Pestoff, Martine Risch, Katharina M. Roetzer, Lucie Slámová, Sonja Strang-Karlsson, Virginie Szymczak, Olga Valcina, Joelle Ronez
|
Nature
Verified
Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia - Leukemia
To the Editor According to the international consensus classification (ICC) nine mutations define acute myeloid leukemia (AML) with myelodysplasia-related gene (MRG) mutations: ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1 and ZRSR2 [1]. Patients with MRG mutations have been shown to be older, leukopenic at diagnosis and overall have a worse outcome [2].
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents - Leukemia
Abstract Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. However, predictors of outcome are elusive. The objective of the current retrospective observational multicenter study of 240 adult patients (median age 68.6 years) with R/R AML was to establish a prognostic risk score. Overall response was documented in 106 (44%) patients. With a median follow-up of 31.5 months, 179 deaths were recorded.
Factors delaying non‐metastatic breast cancer adjuvant therapy and impact on prognosis in a cohort of Brazilian women
• , , , et al. Factors associated with delays in chemotherapy initiation among patients with breast cancer at a comprehensive cancer center . J Natl Compr Cancer Netwk. ; ( ): - . doi:10.6004/jnccn.2016.0163 • , , , , . Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer . Breast Cancer Res Treat. ; ( ): - . doi:10.1007/s10549-020-05910-0 • , , , et al.
Compressive taping to prevent postmastectomy seroma: patient adherence and satisfaction
Abstract Objective Evaluate patient adherence and satisfaction concerning postmastectomy compressive taping. Methods This comprises a preintervention and postintervention study carried out with women ≥18 years old who underwent taping during the first 7 postoperative days at the Cancer Hospital III/National Cancer Institute. Good adherence was considered as taping maintenance for 7 days. Satisfaction levels were classified as satisfied and dissatisfied.
Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia—a case-control study - Leukemia
To the Editor: Today, most children treated for acute lymphoblastic leukemia (ALL) can be cured by the application of intensive combination chemotherapy regimens [1, 2]. However, within 20 years, up to 10% develop a second malignant neoplasm (SMN) with cure rates often being dismal [3, 4]. Therefore, strategies are needed for an early identification of patients at risk for SMN development, an improved understanding of the underlying pathobiology and, ideally, the development of preventive actions.
BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer
1 INTRODUCTION Ovarian cancer (OC) is one of the leading causes of death among gynecological malignancies, with 314,000 new cases and 207,500 deaths per year.1 In Brazil, this type of cancer is the eighth most incident and 7310 new cases per year were estimated for the period 2023-2025.2 Ninety percent of ovarian cancer are derived from epithelial cells (epithelium of ovarian surface or ovarian tube), the remaining 10% are derived from germ cells or from granulosa-theca cells, being 3/4 of OC...
Prevalence and factors associated with the occurrence of pathological fractures and their impact on the overall survival of patients with bone metastases under palliative care
Abstract Objectives To assess the prevalence and factors associated with the occurrence of pathological fractures and their impact on the overall survival of patients with bone metastases under palliative care. Methods An observational retrospective cohort assessment concerning both male and female patients with cancer presenting with bone metastases referred to a palliative care unit. Sociodemographic and clinical data were obtained before and after care unit referral.
Higher severity and risk of in‐hospital mortality for COVID‐19 patients with cancer during the year 2020 in Brazil: A countrywide analysis of secondary data
Abstract BACKGROUND Coronavirus disease 2019 (COVID-19) and cancer are serious public health problems worldwide. However, little is known about the risk factors of in-hospital mortality among COVID-19 patients with and without cancer in Brazil. The objective of this study was to evaluate the risk factors of in-hospital mortality among COVID-19 patients with and without cancer and to compare mortality according to gender and topography during the year 2020 in Brazil.
Determinants of delay from cancer diagnosis to treatment initiation in a cohort of brazilian women with breast cancer
ORIGINAL ARTICLE Anke Bergmann Corresponding Author abergmann@inca.gov.br orcid.org/0000-0002-1972-8777 Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil *Correspondence Anke Bergmann, Instituto Nacional de Câncer ‐ Centro de Pesquisa Clínica, Rua André Cavalcanti, 37 / Anexo ‐ 3o andar ‐ Centro ‐ Rio de Janeiro ‐ RJ ‐ Brazil.
Increased incidence, morbidity and mortality rates for lung cancer in women in Brazil between 2000 and 2014: an analysis of three types of sources of secondary data
Publication HistoryPublished online: September 11, 2018Accepted: September 9, 2018; Received in revised form: August 16, 2018; Received: March 3, 2018;
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Anke
Contact Anke, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack